Viewing Study NCT05089656

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:36 PM
Ignite Modification Date: 2026-05-30 @ 4:18 PM
Study NCT ID: NCT05089656
Status: COMPLETED
Last Update Posted: 2025-12-08
First Post: 2021-10-11
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Type 2 Spinal Muscular Atrophy View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Zolgensma View
None OAV101 View
None AVXS 101 View
None gene therapy View
None Muscle atrophy View
None SMA View
None spinal muscular atrophy View
None muscle function View
None myopathy View
None muscle wasting View
None atrophied muscle View
None loss of muscle strength View
None pediatric View